CHARACTERISTICS OF METABOLIC SYNDROME – (02-21-05)



Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome

Okay.  A couple problems here.  This study reviewed several statin drugs to determine which one lowered lipids better in patients with metabolic syndrome.  You know metabolic syndrome the condition where high INSULIN levels increase lipids.

So here’s my analogy:  Your house is on fire and the smoke detector is going off.  We take a baseball bat, hammer and the wrong end of a screwdriver and beat on the smoke detector to see which one breaks the detector into the smallest pieces.  Forget the fire–that’s not important.

And, just to be consistent with this study for my analogy, Astra Zeneca, the manufacturer of the hammer (which was found to be the most effective), paid for the study.  Suspicious?  And does anyone wonder why they didn’t check corresponding insulin levels?

Read entire article here

James Bogash

For more than a decade, Dr. Bogash has stayed current with the medical literature as it relates to physiology, disease prevention and disease management. He uses his knowledge to educate patients, the community and cyberspace on the best way to avoid and / or manage chronic diseases using lifestyle and targeted supplementation.







Email:



Posted on
Category: Insulin
Disclosure of Material Connection: Some of the links in the post above are “affiliate links.” This means if you click on the link and purchase the item, I will receive an affiliate commission. Regardless, I only recommend products or services I use personally and believe will add value to my readers. I am disclosing this in accordance with the Federal Trade Commission’s 16 CFR, Part 255: “Guides Concerning the Use of Endorsements and Testimonials in Advertising.”